%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-12-08T10:54:49-05:00
2016-12-08T10:55:18-05:00
2016-12-08T10:55:18-05:00
Adobe InDesign CC 2017 (Windows)
uuid:a14a781e-5153-4e75-acf2-1399322dfdba
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:089ac453-591c-4149-a90f-6b4b82335a3e
proof:pdf
xmp.iid:6b34d2c3-d776-b949-8b2e-5b9030c026b1
xmp.did:8cd95f81-5f3f-5f43-831b-f09705e7dc66
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2016-12-08T10:54:49-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
17 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6 (atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 257.75 Tm
(PHARMACOLOGY WATCH)Tj
/T1_1 1 Tf
6 0 0 6 127.892 257.75 Tm
[(\231 is published monthly by AHC Media, LLC. Copyright \251)-10 ( )]TJ
-14.524 -1.167 Td
[(2017 AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
0.01 Tw 8 0 0 8 40.75 240.75 Tm
(Author)Tj
/T1_1 1 Tf
(: )Tj
/T1_3 1 Tf
0 Tw 3.698 0 Td
(William T. Elliott, MD, FACP, )Tj
/T1_1 1 Tf
[(Medical Director, Pharmacy,)-9.9 ( )]TJ
-3.698 -1.25 Td
[(Northern California Kaiser Permanente Assistant Clinical Professor of)-9.9 ( )]TJ
0 -1.25 TD
(Medicine, University of California, San Francisco)Tj
/T1_2 1 Tf
T*
(Assistant Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
/T1_2 1 Tf
0.01 Tw T*
(Editor)Tj
/T1_1 1 Tf
0 Tw (: Jill Drachenberg)Tj
6 0 0 6 40.75 189.25 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10 ( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10 ( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation)-10 ( )]TJ
0 -1.167 TD
[(Council for Continuing Medical Education guidelines, Dr. Elliott, Ms. Dr\
achenberg, and Mr.)-10 ( )]TJ
T*
(Springston report no financial relationships relevant to this field of s\
tudy.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 222.5 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 167.2314 90.3042 cm
0 0 m
81.287 0 l
S
Q
q 1 0 0 1 151.4756 83.3042 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
0.01 Tw (jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
T*
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One Atlanta)-10 ( )]TJ
T*
[(Plaza, 950 East Paces Ferry Road NE, Suite 2850, Atlanta,)-9.9 ( )]TJ
T*
[(GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
44.685 73.418 70.72 32.443 re
W n
/GS1 gs
q 1 0 0 1 52.0285 92.6745 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 70.4899 86.0851 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 88.2162 88.5766 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 95.8269 88.8489 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 103.1923 88.6991 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
106.664 91.463 1.675 -6.63 re
106.664 84.833 m
108.448 93.314 m
108.448 92.824 108.08 92.416 107.495 92.416 c
106.936 92.416 106.569 92.824 106.569 93.314 c
106.569 93.832 106.95 94.227 107.508 94.227 c
108.08 94.227 108.434 93.832 108.448 93.314 c
f
q 1 0 0 1 113.6622 88.0729 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
BT
/T1_4 1 Tf
10 0 0 10 36 746.8399 Tm
[(sion analysis showed a higher risk of pneumonia compared)-10 ( )]TJ
0 -1.211 TD
[(to controls \(1.67 times higher for those exposed to PPI)-10 ( )]TJ
T*
[([95% con\037dence interval, 1.55-1.79]\). But the other two)-10 ( )]TJ
T*
[(analyses showed a lower risk. In the self-controlled study)92.1 (,)-10 ( )]TJ
T*
[(the risk of pneumonia was almost twice as high in the 30)-10 ( )]TJ
0 -1.211 TD
[(days prior to a PPI prescription \(relative risk, 1.92; 95%)-10 ( )]TJ
0 -1.211 TD
[(con\037dence interval, 1.84-2.00\). The prior event ratio also)-10 ( )]TJ
T*
[(showed a higher risk of pneumonia the year prior to PPI)-10 ( )]TJ
T*
[(use compared to the year after)111 (. The authors concluded)-9.9 ( )]TJ
T*
[(that the previously noted association between PPI use)-10 ( )]TJ
T*
[(and community-acquired pneumonia is \223likely to be due)-10 ( )]TJ
0 -1.211 TD
[(entirely to confounding factors.\224 These factors may include)-10 ( )]TJ
0 -1.211 TD
(gastroesophageal re\036ux disease. \()Tj
/T1_5 1 Tf
0.01 Tw (BMJ)Tj
/T1_4 1 Tf
0 Tw ( 2016;355:i5813\))Tj
/TT0 1 Tf
0 Tc 14 0 0 14 36 573.2483 Tm
[(Exploring Therapies to R)18.4 (educe P)36.1 (elvic )]TJ
15.212 0 Td
( )Tj
-15.212 -1.151 Td
[(and Hip F)17.6 (ractures)]TJ
/T1_4 1 Tf
-0.01 Tc 10 0 0 10 36 545.0209 Tm
[(The thiazide diuretic chlorthalidone is associated with a)-10 ( )]TJ
0 -1.211 TD
[(reduced risk of pelvic and hip fractures compared with)-10 ( )]TJ
0 -1.211 TD
[(other antihypertensive drugs, according to a new analysis)-10 ( )]TJ
0 -1.211 TD
[(of the ALLHA)74 (T study)92 (. Nearly 22,000 men and women)-10 ( )]TJ
0 -1.211 TD
[(\(57% and 43%, respectively\) were followed for up to eight)-10 ( )]TJ
T*
[(years during masked therapy and more than 16,600 were)-10 ( )]TJ
T*
[(followed for an additional \037ve years. During the trial, 338)-10 ( )]TJ
T*
[(fractures occurred. Patients randomized to chlorthalidone)-10 ( )]TJ
T*
[(vs. amlodipine or lisinopril demonstrated a lower risk of)-10 ( )]TJ
T*
[(fracture on adjusted analysis \(hazard ratio [HR], 0.79;)-10 ( )]TJ
0 -1.211 TD
(95% con\037dence interval [CI], 0.63-0.89; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.01 Tc 18.038 0 Td
[( = 0.04\). The)-10 ( )]TJ
-18.038 -1.211 Td
[(risk of fracture was signi\037cantly lower with chlorthalidone)-10 ( )]TJ
0 -1.211 TD
(vs. lisinopril \(HR, 0.75; )Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.01 Tc 10.847 0 Td
[( = 0.04\) but not amlodipine \(HR,)-9.9 ( )]TJ
0.01 Tw -10.847 -1.211 Td
(0.82; )Tj
/T1_5 1 Tf
0 Tc 0 Tw 2.442 0 Td
(P)Tj
/T1_4 1 Tf
-0.01 Tc 0.601 0 Td
[( = 0.17\). These \037ndings \223provide evidence of a)-10 ( )]TJ
-3.043 -1.211 Td
(bene\037cial effect of thiazide-type diuretic therapy in reduc)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(ing hip and pelvic fracture risk compared with treatment)-9.9 ( )]TJ
T*
[(with other antihypertensive medications.\224 This study)-10 ( )]TJ
0 -1.211 TD
[(strengthens evidence from other studies that suggested that)-10 ( )]TJ
0 -1.211 TD
[(thiazides improve bone strength and reduce fracture risk by)-10 ( )]TJ
0 -1.211 TD
[(exerting a positive effect on calcium balance and perhaps)-10 ( )]TJ
0 -1.211 TD
(a direct stimulatory effect on osteoblasts. \()Tj
/T1_5 1 Tf
[(JAMA Intern)-10 ( )]TJ
0.01 Tw T*
(Med)Tj
/T1_4 1 Tf
0 Tw [(. Published online Nov)92 (. 21, 2016. doi:10.1001/jamain)]TJ
0 Tc (-)Tj
-0.01 Tc 0.01 Tw T*
(ternmed.2016.6821\))Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 306 743.9232 Tm
[(Notable CO)55.4 (X)50 (-2 Inhibitor Carries Same CV )]TJ
0 -1.151 TD
[(Risks as T)175.3 (raditional NSAIDs)]TJ
/T1_4 1 Tf
-0.01 Tc 10 0 0 10 306 715.6959 Tm
[(Celecoxib \(Celebrex\) has similar cardiovascular risks as)-10 ( )]TJ
0 -1.211 TD
[(traditional NSAIDs, according to a new industry-sponsored)-10 ( )]TJ
T*
[(study)92 (. Celebrex is a COX-2 inhibitor)111 (, similar to rofecoxib)-10 ( )]TJ
T*
[(\(V)37 (ioxx\) and valdecoxib \(Bextra\), which were both re)]TJ
0 Tc (-)Tj
-0.01 Tc T*
[(moved from the market in 2004 and 2005 due to excess)-10 ( )]TJ
T*
[(cardiovascular events. Celecoxib also has been implicated)-10 ( )]TJ
0 -1.211 TD
[(in an increased rate of cardiovascular events compared)-9.9 ( )]TJ
0 -1.211 TD
[(to placebo, but to a lesser extent than the other COX-2)-10 ( )]TJ
-0.001 Tw T*
[(drugs. A new study compared celecoxib to the non-selective)-9.9 ( )]TJ
0 Tw T*
[(NSAIDs ibuprofen and naproxen in patients at risk for)-9.9 ( )]TJ
T*
[(cardiovascular disease to assess cardiovascular safety)92 (. More)-10 ( )]TJ
0 -1.211 TD
[(than 24,000 patients presenting with rheumatoid arthritis)-10 ( )]TJ
0 -1.211 TD
[(or osteoarthritis were randomly assigned to celecoxib 100)-9.9 ( )]TJ
0 -1.211 TD
[(mg twice a day)92 (, naproxen or ibuprofen for a mean treat)]TJ
0 Tc (-)Tj
-0.01 Tc 0 -1.211 TD
[(ment duration of 20 months and a mean follow-up period)-9.9 ( )]TJ
0 -1.211 TD
(of 34 months with a primary outcome of fatal cardiovas)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(cular events or nonfatal stroke or myocardial infarction.)-10 ( )]TJ
T*
[(Nearly 70% stopped taking the trial drug during the study)92 (,)-10 ( )]TJ
T*
[(and 27% discontinued follow-up. In the intention-to-treat)-10 ( )]TJ
T*
(analyses, a primary outcome event occurred in 2.3% of pa)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(tients in the celecoxib group, 2.5% in the naproxen group,)-10 ( )]TJ
T*
[(and 2.7% in the ibuprofen group \(hazard ratio [HR] for)-9.9 ( )]TJ
T*
[(celecoxib vs. naproxen, 0.93; 95% con\037dence interval [CI],)-9.9 ( )]TJ
0 -1.211 TD
[(0.76-1.13; HR for celecoxib vs. ibuprofen, 0.85; 95% CI,)-10 ( )]TJ
0.01 Tw 0 -1.211 TD
(0.70-1.04; )Tj
/T1_5 1 Tf
0 Tc 0 Tw 4.671 0 Td
(P)Tj
/T1_4 1 Tf
-0.01 Tc 0.601 0 Td
( < 0.001 for noninferiority in both compari)Tj
0 Tc (-)Tj
-0.01 Tc -5.272 -1.211 Td
[(sons\). The results were similar in the on-treatment analysis)-10 ( )]TJ
0 Tc T*
(\()Tj
/T1_5 1 Tf
0.323 0 Td
(P)Tj
/T1_4 1 Tf
-0.01 Tc 0.601 0 Td
[( < 0.001 for noninferiority for both comparisons\). The)-9.9 ( )]TJ
-0.924 -1.211 Td
[(risk of gastrointestinal events was signi\037cantly lower with)-10 ( )]TJ
T*
(celecoxib than with naproxen \()Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.01 Tc 13.749 0 Td
( = 0.01\) or ibuprofen \()Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
( )Tj
-0.01 Tc -13.749 -1.211 Td
[(= 0.002\); the risk of renal events was signi\037cantly lower)-10 ( )]TJ
0 -1.211 TD
(with celecoxib than with ibuprofen \()Tj
/T1_5 1 Tf
0 Tc (P)Tj
/T1_4 1 Tf
-0.01 Tc 16.023 0 Td
[( = 0.004\), but was)-10 ( )]TJ
-16.023 -1.211 Td
[(not signi\037cantly lower with celecoxib than with naproxen)-10 ( )]TJ
0 Tc 0 -1.211 TD
(\()Tj
/T1_5 1 Tf
0.323 0 Td
(P)Tj
/T1_4 1 Tf
-0.01 Tc 0.601 0 Td
[( = 0.19\). \(doi: 10.1056/NEJMoa1611593\). In a fairly)-9.9 ( )]TJ
-0.924 -1.211 Td
[(strident critique, Dr)111 (. Garret Fitzgerald suggested the study)-10 ( )]TJ
T*
(was poorly designed and that \223there are so many prob)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(lems with the interpretation of PRECISION that it fails to)-10 ( )]TJ
T*
(inform clinical practice.\224 \()Tj
/T1_5 1 Tf
0.01 Tw (Circulation)Tj
/T1_4 1 Tf
0 Tw [(. Published online)-10 ( )]TJ
T*
[(Nov)92 (. 13, 2016. http://dx.doi.org/10.1161/CIRCULA)]TJ
0 Tc (-)Tj
-0.01 Tc 0.01 Tw T*
(TIONAHA.116.026324.\))Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 305.9999 227.1483 Tm
[(FD)17.4 (A Actions)]TJ
/T1_4 1 Tf
-0.005 Tc 10 0 0 10 305.9999 215.0347 Tm
[(The FDA has approved prasterone to treat women with)-5 ( )]TJ
T*
[(moderate to severe dyspareunia due to menopause-related)-5 ( )]TJ
T*
[(vulvar and vaginal atrophy)92 (. The drug is the \037rst FDA-ap)]TJ
0 Tc (-)Tj
-0.005 Tc T*
(proved product to contain prasterone, also known as de)Tj
0 Tc (-)Tj
-0.005 Tc T*
[(hydroepiandrosterone \(DHEA\). Prasterone is administered)-5 ( )]TJ
T*
[(as a once-daily vaginal insert. Ef\037cacy was established)-5 ( )]TJ
0 -1.211 TD
[(in two 12-week, placebo-controlled trials of 406 healthy)-5 ( )]TJ
0 -1.211 TD
[(women, 40-80 years of age with moderate to severe)-5 ( )]TJ
T*
[(symptoms. Compared to placebo, the prasterone vaginal)-5 ( )]TJ
T*
[(insert reduced the severity of pain experienced during)-5 ( )]TJ
T*
[(sexual intercourse. Safety was established in four 12-week,)-5 ( )]TJ
0 -1.211 TD
[(placebo-controlled trials on one 52-week open-label trial.)-5 ( )]TJ
0 -1.211 TD
(The most common adverse reactions were vaginal dis)Tj
0 Tc (-)Tj
-0.005 Tc 0 -1.211 TD
[(charge and abnormal pap smears. Prasterone vaginal insert)-5 ( )]TJ
0 -1.211 TD
[(is marketed as Intrarosa. )25 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 11.037 0 Td
<0084>Tj
ET
endstream
endobj
24 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 764.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
23 0 obj
<>
endobj
25 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
11 0 obj
<>
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
41 0 obj
<>
endobj
42 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆